Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors
- 27 October 1994
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (17) , 1116-1121
- https://doi.org/10.1056/nejm199410273311703
Abstract
Intestinal adenocarcinomas and various endocrine tumors express large numbers of high-affinity receptors for vasoactive intestinal peptide (VIP). We have evaluated the usefulness of scanning with VIP labeled with iodine-123 for tumor localization in patients with gastrointestinal tumors. Radioiodinated VIP was purified by high-pressure liquid chromatography and administered as a single intravenous bolus injection (300 pmol [1 microgram]). Scanning with radiolabeled VIP was compared with computed tomography and scanning with somatostatin analogues in 79 patients with colorectal cancer, pancreatic carcinoma, gastric cancer, carcinoid tumor, or insulinoma. Visualization of gastrointestinal tumors and metastases was obtained with radiolabeled VIP. Binding of the labeled peptide by primary tumors and metastases was visible shortly after the injection and was still demonstrable at 24 hours. In patients with colorectal adenocarcinomas, primary or recurrent tumors were visualized in 10 of 10, liver metastases in 15 of 1, lung metastases in 2 of 3, and lymph-node metastases in 4 of 4. Primary pancreatic adenocarcinomas were visualized by imaging in 10 of 12 patients, and liver metastases were seen in 7 of 7. Primary or recurrent gastric adenocarcinomas were visualized in five of five patients, and liver metastases were seen in two of two patients. VIP scans were positive in 9 of 10 patients with carcinoid tumors and in 4 of 4 patients with insulinomas. Some tumors with positive VIP scans were also visualized with somatostatin analogues (4 of 17 colorectal adenocarcinomas, 8 of 9 carcinoids, and 2 of 2 insulinomas). In vitro binding studies confirmed the presence of VIP receptors on gastrointestinal tumors. Scanning with radiolabeled VIP can visualize intestinal tumors and metastases that express receptors for VIP.Keywords
This publication has 12 references indexed in Scilit:
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cellsJournal of Neuroimmunology, 1992
- Cloning and expression of the human vasoactive intestinal peptide receptor.Proceedings of the National Academy of Sciences, 1991
- Somatostatin-Receptor Imaging in the Localization of Endocrine TumorsNew England Journal of Medicine, 1990
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989
- Molecular characteristics and evidence for internalization of vasoactive‐intestinal‐peptide (VIP) receptors in the tumoral rat‐pancreatic acinar cell line AR 4‐2 JEuropean Journal of Biochemistry, 1988
- In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells.The Journal of Experimental Medicine, 1984
- Elevated Plasma and Tissue Levels of Vasoactive Intestinal Polypeptide in the Watery-Diarrhea Syndrome Due to Pancreatic, Bronchogenic and Other TumorsNew England Journal of Medicine, 1975
- Vasoactive Intestinal Peptide Stimulation of Adenylate Cyclase and Active Electrolyte Secretion in Intestinal MucosaJournal of Clinical Investigation, 1974
- Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemiaThe American Journal of Medicine, 1958